CD274 and non-small cell lung carcinoma: The patients receiving atezolizumab showed higher OS compared to patients receiving docetaxel.39 Atezolizumab is the first anti-PD-L1 antibody that FDA approved for NSCLC patients whose disease progressed after receiving platinum-derived chemotherapy.40 The IMpower project was carried out to evaluate the efficiency of atezolizumab monotherapy or in combination for NSCLC patients expressing PD-L1 as initial treatment.